

February 27, 2020
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Notice concerning Nominations for the Board of Directors /
the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board**

Symbio Pharmaceuticals Limited (“the Company”) today announced that, pursuant to a resolution passed by the Company’s Board of Directors today, proposals for the election of five (5) directors and one (1) substitute member for the Audit & Supervisory Board will be submitted at the 15th Ordinary General Meeting of Shareholders scheduled for March 26, 2020, as set forth below.

1. Nomination of Candidates for the Board of Directors

(1) Re-nominations

Mr. Fuminori Yoshida, Representative Director, President & CEO

Mr. Shigetoshi Matsumoto, Representative Director (outside director)

Dr. Bruce David Cheson, Representative Director (outside director)

Mr. Rockford Douglas Norby, Representative Director (outside director)

(2) Newly nominated

Mr. Shigeo Kimura, Corporate Officer & CCO

Profile of the Candidate

Date of Birth	June 26, 1963	
Career Summary	April 1986	Squibb Japan Inc. (Bristol-Myers Squibb as of 1990, hereafter BMS)
	January 2007	Marketing Director, Oncology BU, BMS
	May 2011	New Product Planning Director, BMS Canada
	April 2012	Kyushu Chugoku Region Director, Cardiovascular Metabolism Immunology BU, BMS
	January 2013	National Sales Director, CMI BU, BMS
	January 2015	Japan Hematology Franchise Lead, Hematology/Hepatology BU, BMS
	January 2016	Corporate Officer, Commercial Operations BU Head, BMS
	February 2017	Corporate Officer, Oncology BU Head, BMS
	June 2019	Executive Advisor, Symbio Pharmaceuticals Limited
	July 2019	Corporate Officer, Managing Executive Officer, CCO and Head of Japan Business Unit, Symbio Pharmaceuticals Limited

2. Nomination of Candidate as a Substitute Member of the Audit & Supervisory Board

(1) Re-nomination

Mr. Takashi Watanabe as a Substitute Member of the Audit & Supervisory Board (Outside)

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125